Autoantibody signatures: progress and perspectives for early cancer detection.
Autoantibody signatures: progress and perspectives for early cancer detection.
复制标题
自身抗体特征：早期癌症检测的进步和观点。
DOI：
10.1111/j.1582-4934.2011.01355.x
复制
发表时间：
2011-10
影响因子：
5.3
通讯作者：
Solassol J
中科院分区：
文献类型：
--
作者：
Desmetz C;Mange A;Maudelonde T;Solassol J
侵袭性是癌症发展的关键一步，目前的成像技术通常无法检测到肿瘤细胞的早期扩散。在没有明显转移迹象的癌症患者中，已经开发了灵敏的方法来鉴定几种癌症中的循环自身抗体及其抗原对应物。这些技术通常基于蛋白质组学方法，蛋白质和抗体微阵列的最新进展极大地促进了癌症患者血清中新抗体生物标志物的发现。有趣的是，在临床应用环境中，最近已提出将多种自身抗体反应性组合到面板测定中作为相关筛选试验，并在几项独立试验中进行了验证。此外，自身抗体特征似乎与高危癌症患者的癌症早期检测特别相关。在这篇综述中，我们强调的概念，免疫原性表位与体液反应和关键致病途径引起血清自身抗体，可以被认为是相关的癌症生物标志物。我们概述了蛋白质组学策略，用于识别和验证其在癌症筛查和诊断的临床实践中的用途。我们特别强调自身抗体签名在几种癌症中的临床效用。最后，我们讨论了临床验证的挑战。
Becoming invasive is a crucial step in cancer development, and the early spread of tumour cells is usually undetected by current imaging technologies. In patients with cancer and no signs of overt metastases, sensitive methods have been developed to identify circulating autoantibodies and their antigen counterparts in several cancers. These technologies are often based on proteomic approaches, and recent advances in protein and antibody microarrays have greatly facilitated the discovery of new antibody biomarkers in sera from cancer patients. Interestingly, in a clinical application setting, combinations of multiple autoantibody reactivities into panel assays have recently been proposed as relevant screening tests and validated in several independent trials. In addition, autoantibody signatures seem to be particularly relevant for early detection of cancer in high-risk cancer patients. In this review, we highlight the concept that immunogenic epitopes associated with the humoural response and key pathogenic pathways elicit serum autoantibodies that can be considered as relevant cancer biomarkers. We outline the proteomic strategies employed to identify and validate their use in clinical practice for cancer screening and diagnosis. We particularly emphasize the clinical utility of autoantibody signatures in several cancers. Finally, we discuss the challenges remaining for clinical validation.
登录
查看更多内容
影响因子：
11.2
作者：
Fernández-Madrid, F;Tang, NM;Karvonen, RL
通讯作者：
Karvonen, RL
影响因子：
14.8
作者：
Ehrlich, Joshua R.;Qin, Shuzhen;Liu, Brian C-S
通讯作者：
Liu, Brian C-S
影响因子：
15.3
作者：
Gaudin, E;Hao, Y;Freitas, AA
通讯作者：
Freitas, AA
影响因子：
11.5
作者：
Desmetz, Caroline;Bascoul-Mollevi, Caroline;Solassol, Jerome
通讯作者：
Solassol, Jerome
DOI：
10.1073/pnas.94.5.1914
发表时间：
1997-03-04
影响因子：
11.1
作者：
Chen, YT;Scanlan, MJ;Old, LJ
通讯作者：
Old, LJ